Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07337564 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Shandong First Medical University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modifiedv2 Show 4 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Feb 1, 2026 to Jan 29, 2026
    • Secondary endpoints revised (3)
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study was designed to assess the therapeutic efficacy and safety of SHR-1139 Injection in adult patients with ulcerative pyoderma gangrenosum.
Trial Details
NCT Number NCT07337564
Lead Sponsor Shandong First Medical University
Conditions
(from sponsor)		 Pyoderma Gangrenosum
Related terms Pyoderma Gangrenosum
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov